High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
暂无分享,去创建一个
B. Hiddinga | C. H. van der Leest | A. Dingemans | M. M. van den Heuvel | A. D. de Langen | A. ter Elst | A. van der Wekken | L. Hendriks | S. Hashemi | B. van Veggel | T. Hiltermann | F. Zwierenga | Lucie B.M. Hijmering – Kappelle
[1] S. Kobayashi,et al. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios , 2021, Cells.
[2] S. Matsumoto,et al. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. , 2021, Lung cancer.
[3] Jing Wang,et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC , 2021, Nature.
[4] N. Girard,et al. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Jänne,et al. Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. , 2021 .
[6] Gregory Riely,et al. Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study. , 2021 .
[7] M. Socinski,et al. Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). , 2021, Journal of Clinical Oncology.
[8] J. Neal,et al. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. , 2021, Cancer discovery.
[9] Y. Zhang,et al. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations. , 2020, Lung cancer.
[10] S. Kobayashi,et al. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. , 2020, The oncologist.
[11] M. Socinski,et al. Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. , 2020 .
[12] L. Sequist,et al. ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. , 2020 .
[13] E. Felip,et al. New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. , 2020, Critical reviews in oncology/hematology.
[14] S. Kobayashi,et al. EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors , 2020, JTO clinical and research reports.
[15] E. Schuuring,et al. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. , 2019, Lung cancer.
[16] Ying Cheng,et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.
[17] D. Heo,et al. Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19) , 2019, Annals of Oncology.
[18] S. Kobayashi,et al. TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations , 2019, Molecular Cancer Research.
[19] Minghui Wang,et al. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer , 2019, BMC Cancer.
[20] J. McPherson,et al. Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] F. Cappuzzo,et al. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. , 2018, Journal of thoracic disease.
[22] Kwok-Kin Wong,et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer , 2018, Nature Medicine.
[23] R. Rosell,et al. Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. , 2018, Translational lung cancer research.
[24] P. Jänne,et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] Chia-Chi Lin,et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Ahn,et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.
[27] T. Mitsudomi,et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. , 2016, The Lancet. Oncology.
[28] P. Jänne,et al. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies , 2016, Cancer Chemotherapy and Pharmacology.
[29] T. Betsuyaku,et al. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer , 2015, Oncotarget.
[30] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[31] Geoffrey R. Oxnard,et al. Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer , 2013, Science Translational Medicine.
[32] Suzanne E Dahlberg,et al. Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[33] Marc Ladanyi,et al. EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics , 2013, Molecular Cancer Therapeutics.
[34] Joseph O. Deasy,et al. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .
[35] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[36] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[37] N. Normanno,et al. The role of EGF-related peptides in tumor growth. , 2001, Frontiers in bioscience : a journal and virtual library.
[38] Wolzt,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.
[39] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.